Loading
A phase 1 trial of IBI3009 in unresectable, metastatic or extensive-stage small-cell lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer is a phase 1 interventional study registered as NCT06613009 by Innovent Biologics (Suzhou) Co. Ltd.; 190 participants are planned, it started on 2024-12-30; the registry gives 2027-08-30 as its primary completion date. Interventions recorded: IBI3009. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Innovent Biologics and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Innovent Biologics and the tag pipeline.
Shares Innovent Biologics and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Innovent Biologics and the tag pipeline.
Shares Innovent Biologics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/